Notice: Internet Explorer 11 users may encounter issues loading pages throughout the website. Please turn on IE-11’s compatibility mode while we work to resolve the issue.

>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

FDA Limits Acetaminophan in Prescription Combination Products

Monday, January 17, 2011

The U.S. Food and Drug Administration (FDA) is asking manufacturers of prescription products that contain acetaminophen to limit its amount to no more than 325 milligrams. The FDA is requiring each manufacturer to update labels of all prescription combination acetaminophen products to warn of the potential risk for severe liver injury.  Over-the-counter acetaminophen products are not affected by this FDA action.

Acetaminophen is a drug that relieves pain and fever. It is combined in many prescription products with other ingredient, usually opioids.  The reason for this FDA action is because of continued reports of liver injury, though most of the cases of severe liver damage occurred in patients who took more than the prescribed dose.

« Back to Washington Alerts